ESC Premium Access

PCSK9 inhibitors: from cells to patients

Event: ESC CONGRESS 2019
Topic: PCSK9-Antagonists
Session type: Advances in Science
Date: 2 September 2019
Time: 08:30 - 10:00

Congress Session

5 presentations in this session

State of the Art - PCSK9 in inhibitors therapy in clinical therapy

Speaker: Professor S. Nicholls (Melbourne, AU)

The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells

Speaker: Doctor O. Itzhaki Ben Zadok (Petah Tikva, IL)

The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.

Speaker: Mrs A. Tsouka (Ioannina, GR)

Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use

Speaker: Doctor S. Mulverstedt (Copenhagen, DK)

Positioning PCSK9 inhibitors therapy in clinical practice.

Speaker: Professor K. Ray (London, GB)

5 speakers from this session

Professor Stephen Nicholls

Monash Heart, Melbourne (Australia)
36 presentations
1 follower

Doctor Osnat Itzhaki Ben Zadok

Rabin Medical Center, Petah Tikva (Israel)
0 follower

Mrs Aikaterini Tsouka

University of Ioannina, Ioannina (Greece)
0 follower

Doctor Stefan Mulverstedt

Bispebjerg University Hospital, Copenhagen (Denmark)
0 follower

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
59 presentations
1 follower

This platform is supported by

logo Novo Nordisk